BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30591199)

  • 1. Telomerase Expression in a Series of Melanocytic Neoplasms.
    de Unamuno Bustos B; Sahuquillo Torralba A; Moles Poveda P; Pérez Simó G; Simarro Farinos J; Llavador Ros M; Palanca Suela S; Botella Estrada R
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):212-219. PubMed ID: 30591199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
    Krengel S; Grotelüschen F; Bartsch S; Tronnier M
    J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of galanin in melanocytic tumors].
    Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
    Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
    Guttman-Yassky E; Bergman R; Manov L; Sprecher E; Shaefer Y; Kerner H
    J Cutan Pathol; 2002 Jul; 29(6):341-6. PubMed ID: 12135464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
    Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
    Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
    Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
    J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis.
    Motaparthi K; Kim J; Andea AA; Missall TA; Novoa RA; Vidal CI; Fung MA; Emanuel PO
    J Cutan Pathol; 2020 Aug; 47(8):710-719. PubMed ID: 32202662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
    Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
    Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferative activity of primary cutaneous melanocytic tumours.
    Kuwata T; Kitagawa M; Kasuga T
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of E-cadherin expression pattern in melanocytic nevi and cutaneous malignant melanoma.
    Seleit IA; Samaka RM; Basha MA; Bakry OA
    Anal Quant Cytopathol Histpathol; 2012 Aug; 34(4):204-13. PubMed ID: 23016467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nestin expression in cutaneous melanomas and melanocytic nevi.
    Brychtova S; Fiuraskova M; Hlobilková A; Brychta T; Hirnak J
    J Cutan Pathol; 2007 May; 34(5):370-5. PubMed ID: 17448190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
    Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
    Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors.
    Sprecher E; Bergman R; Meilick A; Kerner H; Manov L; Reiter I; Shafer Y; Maor G; Friedman-Birnbaum R
    J Cutan Pathol; 1999 Feb; 26(2):72-7. PubMed ID: 10082396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
    Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
    Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.